Search by alphabetical order

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Back

Marina Klein, MD, M.Sc., FRCPC

Senior Scientist, RI-MUHC, Glen site

Infectious Diseases and Immunity in Global Health Program

Professor, Department of Medicine, Division of Infectious Diseases, Faculty of Medicine, McGill University

 

Keywords


HIV • Hepatitis C • clinical trials • epidemiology • antiretrovirals • prospective cohort

Research Focus


My research focuses on the treatment of patients with HIV and chronic hepatitis. As a prominent researcher in clinical and epidemiologic aspects of HIV and Hepatitis C co-infection, I lead one the largest multicenter cohorts focused on HIV/HCV co-infection in the world, recruiting more than one thousand HIV/HCV co-infected patients across Canada. The primary objectives of the CIHR funded cohort are to study the interactions between these two chronic viruses and their natural history in the era of combination antiretroviral therapy (cART) and to evaluate therapeutic strategies aimed at improving health outcomes in co-infected persons. We are also focused on understanding the roles of co-morbidities in the natural history of HIV/HCV co-infection. In addition, I am involved in a number of observational epidemiologic research collaborations (NA-ACCORD and CANOC) that focus on understanding long term clinical and treatment outcomes in HIV infection. My other research interests include antiretroviral pharmacoepidemiology and HIV infection in women.

Selected Publications


Click on Pubmed to see my current publications list

  • Saeed S, Strumpf E, Walmsley W, Rollet-Kurhajec K, Pick N, Martel Laferriere V, Hull M, Gill MJ, Cox J, Cooper C, Klein MB. How generalizable are the results from trials of Direct Antiviral Agents to people co-infected with HIV/Hepatitis C virus in the real world. Clin Infect Dis 2016. pii: civ1222.

  • Brunet L, Moodie EEM, Young J, Cox J, Hull M, Cooper C, Walmsley S, Martel-Laferriere V, Rachlis A, Klein MB for the Canadian Coinfection Cohort Study Investigators. Progression of liver fibrosis and modern combination antiretroviral therapy regimens in HIV-hepatitis C co-infected persons. Clin Infect Dis 2016. 62(2): 242-9. doi: 10.1093/cid/civ838.

  • Yeung MW, Young J, Moodie EEM, Rollet-Kurhajec KC, Schwartzman K, Greenaway C, Cooper C, Cox J, Gill MJ, Hull M, Walmsley S, Klein MB, for the Canadian Coinfection Cohort Study Investigators. Changes in quality of life, health care use and substance use in HIV- Hepatitis C coinfected patients after Hepatitis C therapy: a prospective cohort study. HIV Clin Trials 2015. 16(3): 100-110. doi: 10.1179/501100000024.

  • Hull M, Shafran S, Tseng A, Giguère P, Klein MB, Cooper C. CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults. Can J Infect Dis Med Microbiol 2014 Nov-Dec;25(6):311-20.

  • Klein MB, Saeed S, Yang H, Cohen J, Conway B, Cooper C, Côté P, Cox J, Gill J, Haase D, Haider S, Montaner J, Pick N, Rachlis A, Rouleau D, Sandre R, Tyndall M, Walmsley S. Cohort Profile: The Canadian HIV-Hepatitis C Co-infection Cohort Study. Int J Epidemiol 2010; 39(5):1162-9. PMID: 19786463.